[{"Assets_0_Q3_USD":9834866000.0,"CommonStockSharesOutstanding_0_Q3_shares":226763072.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":119244000.0,"NetIncomeLoss_1_Q3_USD":-79415000.0,"NetIncomeLoss_3_Q3_USD":-203993000.0,"StockholdersEquity_0_Q3_USD":-661477000.0,"EarningsPerShareBasic_1_Q3_USD":-0.35,"EarningsPerShareBasic_3_Q3_USD":-0.9,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":226598000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":225804000.0,"Ticker":"ENDP","CIK":"1593034","name":"ENDO INTERNATIONAL PLC","OfficialName":"Endo International plc Ordinary Shares","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"640358301.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20191104"}]